Several genes associated with HSP phenotypes disturb lipid metabolic pathways as a potential therapeutic target, including CYP7B1, EPT1, PCYT2, DDHD1, DDHD2, PNPLA6, B4GALNT1, CYP2U1, FA2H, GBA2, PLA2G6, ATP13A2, BSCL2, C19orf12, ERLIN2, SPART, SPAST, SPG11, SPG15, ATL1 and REEP1 [108]. Here, ATP13A2 is linked to hereditary spastic paraplegia.